The difference between acalabrutinib and zanubrutinib

Acalabrutinib (Acalabrutinib) and zanubrutinib (Zanubrutinib) are both BTK (brutinib) inhibitors category, used to treat B cell malignancies, especially chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Although they share similar mechanisms, there are some differences in molecular structure, selectivity, pharmacokinetics, and clinical applications.

1. Molecular structure and chemical properties:

Acotinib: is a selective, irreversible BTK inhibitor and belongs to the second generation BTK inhibitor. It inhibits the B cell signaling pathway by binding to the cysteine u200bu200bsite of BTK.

Zanubrutinib: It is also a BTK inhibitor and belongs to the second generation BTK inhibitor. Like acotinib, zanubrutinib inhibits the B cell signaling pathway by binding to BTK.

2. Selectivity and affinity:

Acotinib: Compared with other BTK inhibitors, acotinib has higher selectivity, more accurately interferes with the signaling channels of cancer cells, and reduces the adverse effects on normal cells.

Zanubrutinib: It also has high selectivity and can more accurately interfere with abnormally activatedB cell signaling pathways.

3. Pharmacokinetics:

Acotinib: The half-life in the body is relatively short, requiring two or more daily doses.

Zanubrutinib: In contrast, zanubrutinib has a longer half-life, and the therapeutic effect can usually be maintained if administered once a day.

4. Clinical studies and indications:

Acotinib: Currently approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In addition, acotinib has also achieved some positive results in studies of other B cell malignancies.

Zanubrutinib: It is also approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), and zanubrutinib has shown efficacy in drug-resistant patients in some studies.

5. Adverse reactions and tolerability:

Acotinib: In clinical trials, acotinib showed relatively good tolerability, with common adverse reactions including headache, hypertension and bleeding.

Zanubrutinib: It also shows good tolerability, and adverse reactions include headache, bleeding, etc.

6. Medication plan:

Acotinib: Usually administered twice daily, clinically recommended to be taken after meals.

Zarubrutinib: Usually administered once daily, before or after a meal.

7.Considerations for Special Populations:

Acotinib: Dose adjustment may be necessary in elderly patients and patients with hepatic impairment.

Zanubrutinib: Safety and efficacy have been demonstrated in elderly patients.

Overall, both acotinib and zanubrutinib demonstrated good efficacy and safety in the treatment ofBcell malignancies. The choice of which drug to use should be based on the patient's specific condition, the doctor's recommendations, and the latest results of clinical studies. Patients need to pay close attention to the doctor's instructions during medication and promptly report any discomfort and changes to ensure the best therapeutic effect.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.